Chonluten caps #60

$60.65

  • Availability: In Stock

  • 2 or more $57.50
  • 3 or more $54.50

Indications

Chronic respiratory failure; chronic cardiopulmonary failure; distress syndrome; chest injury.

Recommended


- chronic respiratory failure
- in chronic cardio-pulmonary insufficiency
- after pneumonia
- with the consequences of prolonged artificial ventilation
- with distress syndrome
- with pulmonary tuberculosis in remission
- injuries of the chest
- burns of the upper respiratory tract
- with the consequences of toxic lung lesions, including carbon monoxide poisoning
- with intensive sports
- to maintain the function of the respiratory system in the elderly and senile.

Method of application


Adults take 1-2 capsules 1-2 times a day with meals. Duration of administration 10-30 days. It is advisable to repeat the course after 4-6 months.

In the process of learning Chonluten side effects, complications and drug dependence is not revealed.

Contraindications: individual intolerance of components, pregnancy, breast-feeding.

Side effects when using Chonluten not revealed.

Store in a dry, dark place at room temperature.

Composition


Peptide complex as-7-(glycine, glutamic acid, aspartic acid). Excipients: microcrystalline cellulose (E460), beet sugar, lactose, starch, twin-80. As an additional source of peptides.

Contraindications


Individual intolerance of components, pregnancy, breast-feeding. It is recommended to consult a doctor before use.

Description


Bioregulator normalization of lung function and bronchial mucosa.

Chonluten is a peptide complex containing amino acids that contribute to the normalization of lung function and bronchial mucosa.

The clinical study established the effectiveness of Chonluten in the comprehensive prevention and treatment of patients with impaired lung and bronchial function in acute and chronic respiratory diseases of infectious and non-infectious origin, as well as to maintain the function of the respiratory system in the elderly and senile age.

It is possible to use Chonluten to reduce the frequency of coughing and choking attacks, reduce the amount of sputum.

Chonluten is recommended to take 1-2 capsules 1-2 times a day with meals. The length of treatment is 20-30 days. It is advisable to repeat the course after 4-6 months.

The clinical study of the effectiveness of Chonluten was carried out with the participation of 47 patients with chronic bronchitis with an asthmatic component in remission, including 26 men and 21 women aged 38 to 65 years, who made up the main group.

Patients complained of coughing with sputum, mainly in the morning, General weakness, sweating, shortness of breath during exercise, intermittent attacks of suffocation, sleep disturbance, headaches. Patients of the main group received in addition to conventional drugs Chonluten 1-2 tablets 2 times a day for 20-30 days, depending on the severity of the pathological process. 29 patients of the control group with a similar disease received only conventional treatments.

Patients ' complaints were evaluated in dynamics, General clinical study of blood and urine, biochemical study of blood was carried out. Lung radiography, sputum microscopic examination and analysis of respiratory function were performed.

It was found that the use of Chonluten in addition to conventional therapy in 82% of patients with chronic bronchitis with an asthmatic component contributed to improving health, reducing the frequency of coughing and choking attacks, reducing the amount of sputum, improving physical performance. Auscultation of the lungs in dynamics indicated the disappearance in some cases of dry whistling and buzzing wheezes. Improved indicators of respiratory function. During the application of Chonluten, a decrease in microscopic structures of sputum was observed: leukocytes, epithelial cells, Kurshman spirals, which indicates a decrease in inflammatory and bronchospastic manifestations of the disease.

Thus, the results of the study indicate the effectiveness and appropriateness of the use of Chonluten for patients suffering from chronic bronchitis.